NCT04342325View on ClinicalTrials.gov

The Clinical Trial of ADR-001 for IgA Nephropathy

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 15, 2020

Primary Completion Date

November 1, 2022

Study Completion Date

March 31, 2023

Conditions
Glomerulonephritis , IGA
Interventions
BIOLOGICAL

infusion of ADR-001 (Mesenchymal stem cell)

Once or twice with two week interval at a dose of 100 x 10 \^ 6 cells.

Trial Locations (2)

486-8510

Kasugai Municipal Hospital, Kasugai

566-8560

Nagoya University Hospital, Nagoya

All Listed Sponsors
collaborator

Rohto Pharmaceutical Co., Ltd.

INDUSTRY

lead

Nagoya University

OTHER

NCT04342325 - The Clinical Trial of ADR-001 for IgA Nephropathy | Biotech Hunter | Biotech Hunter